【摘要】 目的 观察重组人白介素-11(rhIL-11)对恶性肿瘤患者化疗所致血小板减少的治疗效果及不良反应。方法 化疗后24h给予rhIL-11每天50μg/d皮下注射，观察外周血小板变化。结果 血小板升至>100×109/L所需时间：Ⅱ度21例(3.4±1.8)天，Ⅲ度9例(6.7±1.5)天，Ⅳ度1例15天。主要不良反应为乏力、水肿、关节肌肉疼痛、心律失常及发热。结论 重组人白介素-11(rh1-11)有提升化疗后血小板减少的治疗作用；不良反应可耐受。

    【关键词】 血小板减少症；重组人白介素-11；恶性肿瘤；化学治疗

    Clinical evaluation of recombinant human interleukin-11 therapy for chemotherapy induced thrombocytopenia

    LI Yi-gang,LAI Shu-zhen,LU Lu-ding,et al.

    Yuebei People’s Hospital,Shaoguan 512026,China

    【Abstract】 Objective To observe the efficacy and tocicity of recombinant human interleukin-11 therapy for chemotherapy-induced thrombocytopenia in patients with malignant tumor.Methods 31 patients with chemotherapy induced thrombocytopenia involved.The rhIL-11 dose was 50ug per day.Observed the time required to platelet increased to 100×109/L.Results The time to grade Ⅱ thrombocytopenia was 3.4±1.8 days,and that of grade Ⅲ/Ⅳ were 6.7±1.5 and 15 days.Major side effects were fatigue,edema,arthralgia/muscle pain,arrhythmia and fever.Conclusion rhIL-11 can elevate blood platelet count and are tolerable and a effective drug for treatment of chemotherapy induced thrombocytopenia. ......